USSTOCK.TODAY
Market Closed
Log in Sign up

Steady Revenue Growth for Johnson & Johnson vs. Stagnant Revenue for Novo Nordisk

The Motley Fool +1 · ·by G4L

JNJ Johnson & Johnson
$278.70 -1.36%
View chart & analysis →
  1. 1Johnson & Johnson possesses 28 products and platforms that each generate more than $1 billion in annual revenue.
  2. 2Novo Nordisk is struggling to find sales momentum as competitors catch up with their own weight-loss products.
  3. 3While Johnson & Johnson shows a trend of steady quarterly revenue growth, Novo Nordisk's revenue remains mostly stagnant except for a single surge.

So what's the key point?

Johnson & Johnson's revenue is growing steadily, but Novo Nordisk's revenue is staying nearly the same. Novo Nordisk is having difficulty increasing sales as competitors release weight-loss products.

Source The Motley Fool +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →